Gary Woodnutt
Senior Vice President of Translational Sciences & Preclinical DevelopmentDr. Gary Woodnutt, Ph.D., serves as Senior Vice President of Translational Sciences and Preclinical Development at ContraFect Corporation since June 2021. He serves as Chief Scientific Officer of Transposagen Biopharmaceuticals, Inc. Dr. Woodnutt served as Chief Scientific Officer of Tanabe Research Laboratories U.S.A. Dr. Woodnutt served as the Chief Scientific Officer of Lpath Inc. until October 14, 2016 and served as its a Senior Vice President since September 16, 2015 until October 14, 2016. Dr. Woodnutt served as Senior Vice President of Research at Lpath Inc. from April 16, 2013 to September 16, 2015. He served as Vice President of Biology of CovX Research LLC, since March 2006. He joined CovX in March, 2006 as Head of Biology. He served as a Director of Biology at CovX Research LLC. He served as the Vice President of Open Innovation at Pfizer/CovX from 2012 to 2013 and also served as its Vice President of Biology Research at CovX from 2006 to 2012. He was in his primary role at CovX, from 2006 to 2012. He began his career in the pharmaceutical industry with Glaxo SmithKline Pharmaceuticals, where he served for more than 20 years and served as Vice President and Head of Biology in the Antimicrobial and Host Defense Group. He served as the Head of Pharmaceutical Research & Development at Diversa. From 2002 to 2006, he served as the Senior Vice President of Pharmaceutical Research & Development for Diversa Corporation. He served at GlaxoSmithKline where he served as Vice President of biology, microbial, musculoskeletal & proliferative disease CEDD and was responsible for discovery and non-clinical development and market support activities in the anti-infective and host defense areas and played a key role in the development and launch of a number of successful antibiotics, including Augmentin, Timentin and Bactroban. He was employed at BASF Enzymes LLC. He has experience in the pharmaceutical industry. He has an extensive experience in drug discovery and pharmaceutical research. He served at Verenium Corporation. He serves on the Editorial Board of Antimicrobial Agents and Chemotherapy and is a Section Editor for Drug Discovery Today: Therapeutic Strategies and Current Opinion in Biotechnology. He has authored numerous scientific articles. Dr. Woodnutt has B.S. degree in Biochemistry and Physiology at the University of Leeds in 1977 and his Ph.D. degree in Biochemistry and Physiology from the University of Reading in 1980.
Positions
- Company NameContraFect CorporationStock CodeCFRXQPositionSenior Vice President of Translational Sciences & Preclinical DevelopmentColleagues
- MMMichael MessingerCEO, President, CFO & Principal Accounting Officer
- RJRoger James PomerantzChairman
- NBNatalie BogdanosGeneral Counsel, Corporate Secretary & Data Protection Officer
- MSMatthew SalamoneVice President of Human Resources
- WGWilliam Garrett NicholsInterim Chief Medical Officer
- SCSteven C. GilmanVice Chairman
- VAVincent A. FischettiChairman of Scientific Advisory Board
- SJSol J. BarerLead Independent Director
- DNDavid N. LowIndependent Director
